Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional)
ID: 359144Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359144

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-26-001.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional)" aimed at supporting multidisciplinary research to enhance technologies for infertility treatment, particularly through Assisted Reproductive Technologies (ART). This initiative seeks to fund innovative projects that lead to the development of validated technologies, with a phased award structure allowing for up to five years of support—two years for the exploratory R61 phase (no clinical trials) and up to three years for the developmental R33 phase (clinical trials permitted). The NIH plans to allocate $3.3 million in FY 2026 to fund up to 11 R61 awards, with the potential for up to 7 projects to transition to the R33 phase. Interested applicants can find more information and application details at the provided link and should direct inquiries to grantsinfo@nih.gov, with the application deadline set for November 20, 2025.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-HD-26-001-Full-Announcement.html
    RFA-HD-26-001.html
    The Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) have issued a funding opportunity (RFA-HD-26-001) for multidisciplinary research to develop or improve technologies for infertility treatment, especially in Assisted Reproductive Technologies (ART). The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) aims to fund projects that lead to innovative and validated technologies for clinical development. This phased award (R61/R33) offers up to five years of support, with two years for the R61 exploratory phase (no clinical trials) and up to three for the R33 developmental phase (clinical trials allowed). The NOFO details scope, eligibility (including foreign organizations), application instructions, review criteria emphasizing innovation and feasibility, and award administration. The NIH intends to commit $3.3 million in FY 2026 to fund up to 11 R61 awards, with up to 7 transitioning to the R33 phase.
    Similar Opportunities
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research grants (R21) aimed at developing innovative technologies in biomedical research. This initiative seeks applications that propose high-risk, high-reward projects focused on technology development without existing proof of concept, specifically excluding clinical trials. The funding amount is capped at $275,000 in direct costs over two years, with a maximum of $200,000 available in any single year. Interested applicants, including higher education institutions and nonprofit organizations, must adhere to submission guidelines and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The application deadline is January 7, 2028.
    Infertility Training Center
    Office of the Assistant Secretary for Health
    The Office of the Assistant Secretary for Health is offering a federal grant opportunity to establish an Infertility Training Center, aimed at enhancing infertility diagnostic treatments and referrals for patients at Title X-funded clinics. The center will provide training and technical assistance to Title X grantees, focusing on educating about the root causes of infertility, promoting access to holistic treatments, and improving referrals to specialists. With an estimated total program funding of $1.5 million and a single award anticipated, interested applicants, which may include any public or private nonprofit entity, should note that the application deadline is expected to close on August 15, 2025, with awards anticipated by September 30, 2025. For further inquiries, applicants can contact Amy Margolis at amy.margolis@hhs.gov or by phone at 240-453-2820.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.
    Biological Testing Facility for Contraception & Reproductive Health
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for access to a state-of-the-art Biological Testing Facility (BTF) aimed at advancing contraceptive and reproductive health-related product development. This initiative seeks to support innovative and validated methods for fertility regulation and the development of new therapies in reproductive health, addressing a critical need for effective fertility regulation methods. While applications are not currently being solicited, potential applicants are encouraged to prepare their projects in anticipation of the opportunity, with an estimated synopsis post date of October 6, 2025, and an estimated award date of February 23, 2026. For further inquiries, interested parties can contact Dr. Leigh Allen at leigh.allen@nih.gov or by phone at 301-594-9151.
    Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is offering a funding opportunity titled "Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)." This initiative aims to support the development of non-hormonal contraceptives and reproductive health products by providing access to a state-of-the-art facility that offers preclinical services, including protein generation, high throughput screening, and drug metabolism studies. The program is designed to facilitate research that leads to safe and effective reproductive health therapies, with a focus on innovation and scientific merit in project proposals. Applications are open from September 3, 2023, with deadlines on October 3 and April 3 annually until 2026. Eligible applicants include various organizations such as higher education institutions, non-profits, and tribal governments. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This funding opportunity aims to support exploratory research projects that focus on the development and validation of innovative technologies designed to enhance the understanding of cancer biology, improve early detection, and address cancer health disparities. The program is part of the Innovative Molecular Analysis Technologies (IMAT) initiative and is particularly interested in projects that have overcome major feasibility gaps, as evidenced by preliminary data, but still require further validation for broader adoption in the research community. The total estimated funding for this program is $4.5 million, with individual awards ranging from $50,000 to $150,000, and a total of nine awards expected. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information. The application deadline is April 10, 2026, with awards anticipated to be made by December 1, 2026.
    NICHD Small Research Grant Program (R03 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03 Clinical Trial Required) to support clinical trials aligned with the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This program aims to fund small-scale research projects, including pilot studies and methodological development, with a maximum budget of $50,000 per year for up to two years. The funding is crucial for advancing knowledge in human development fields, particularly in childhood development and rehabilitation medicine. Interested applicants must adhere to specific guidelines and register with Grants.gov and eRA Commons, with the application window opening on January 16, 2025, and closing on January 8, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This funding opportunity supports projects through two phases: R61 for non-clinical activities and R33 for small clinical studies, with a focus on ensuring compliance with Environmental Health and Safety regulations. The program emphasizes diversity in applicant teams and requires a Plan for Enhancing Diverse Perspectives, with key deadlines including submission openings starting December 28, 2024, and a close date of January 28, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) to support innovative research projects in the early stages that can lead to significant advancements in biomedical, behavioral, and clinical research. This funding opportunity requires applicants to propose at least one clinical trial and is aimed at addressing critical gaps in knowledge within the scientific missions of participating NIH Institutes and Centers. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and foreign entities, with a total project period limited to two years and a budget of up to $275,000. The application period opens on January 16, 2025, and closes on January 8, 2028; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.